New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Rhea-AI Summary
Arcutis (Nasdaq: ARQT)/b) announced publication of new expert consensus guidance on in the American Journal of Clinical Dermatology. Developed by the Arcutis-supported Genital Psoriasis Wellness Consortium, the paper provides age-specific recommendations for pediatric, adult, and older patients, emphasizing routine genital assessment, empathetic communication, and individualized treatment. Genital involvement affects about two-thirds of the nine million people with plaque psoriasis in the United States. The guidance advises minimizing long-term topical corticosteroid use and considering non-steroidal options where appropriate.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ARQT was down 3.17% while key peers were mixed: APGE up 2.28%, TARS down 1.39%, AGIO down 5.99%, IRON down 4.36%, TVTX down 2.75%. Only TARS appeared in momentum scans, moving up, so ARQT’s move looks stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 26 | Conference presentation | Neutral | +0.2% | Management scheduled a fireside chat at a major healthcare conference. |
| May 08 | Inducement grants | Neutral | +0.3% | Reported RSU and option grants to new employees under inducement plan. |
| May 06 | Q1 2026 earnings | Negative | -14.5% | Q1 results showed strong ZORYVE revenue but drove a notable share price drop. |
| Apr 27 | sNDA submission | Positive | +0.7% | Submitted sNDA to expand ZORYVE cream use in infant atopic dermatitis. |
| Apr 22 | Guideline endorsement | Positive | +1.8% | ZORYVE cream received strong recommendation in new AAD pediatric guidelines. |
Recent company-specific news has generally seen modestly positive or muted reactions, with earnings updates drawing the only pronounced negative move.
Over the last few months, Arcutis has reported a mix of corporate, clinical, and financial updates. In April 2026, ZORYVE received a strong recommendation in new pediatric atopic dermatitis guidelines and an sNDA was submitted to expand its use to infants. The Q1 2026 earnings release combined strong ZORYVE revenue with a notable share price decline of -14.52%. Subsequent items, including inducement grants and a conference presentation announcement, saw only small price changes. Today’s consensus manuscript continues the theme of education and standards-of-care elevation.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration filed on 2026-02-25, covering multiple security types for potential future offerings. As of the latest data, it shows 0 recorded uses in prospectus supplements.
Market Pulse Summary
This announcement highlighted expert, age-specific guidance for diagnosing and managing genital psoriasis, an under-recognized manifestation affecting more than 60% of individuals with psoriasis at some point. It reflects Arcutis’ broader emphasis on education and standards-of-care, complementing recent clinical and guideline milestones for ZORYVE. Investors may watch how such thought-leadership efforts support clinician adoption over time and track future updates alongside prior events like the Q1 2026 results and pediatric atopic dermatitis guideline endorsement.
Key Terms
genital psoriasis medical
psoriatic disease medical
delphi process technical
non-steroidal medical
AI-generated analysis. Not financial advice.
- Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations
- This is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert clinicians
- Genital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis in the United States
WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of a new manuscript in the American Journal of Clinical Dermatology by the Genital Psoriasis Wellness Consortium. This second publication from the Consortium builds upon prior consensus work by providing healthcare providers with clinically practical, expert-driven guidance to help improve the recognition, diagnosis, and management of genital psoriasis across pediatric, adult, and older populations.
The paper emphasizes the importance of routine assessment, empathetic communication, and age-appropriate, individualized treatment approaches to address persistent gaps in care for this under-recognized and under-treated aspect of the condition. The guidance is organized by demographic group rather than overarching themes, offering meaningful, real-world value and ease of application for clinicians treating individuals with this chronic inflammatory skin condition.
“Genital psoriasis is one of the most impactful, yet consistently overlooked, manifestations of psoriatic disease. Although it will affect the majority of individuals with psoriasis at some point in their lives, genital psoriasis remains vastly under diagnosed because clinicians aren't routinely asking and patients are hesitant to bring it up due to its sensitive nature,” said Michael J. Payette, MD, MBA, FAAD, Dermatologist at Central Connecticut Dermatology, Associate Clinical Professor at UConn Health, Genital Psoriasis Consortium member, and manuscript lead author. “Our consensus work represents a 'call to action' and an important step forward, giving clinicians a comprehensive, age-specific roadmap to approach genital psoriasis with the same rigor they bring to every other aspect of dermatologic care. It has the potential to meaningfully direct the course of outcomes for individuals with genital psoriasis who have gone either undiagnosed or untreated for far too long.”
The manuscript was developed through a modified Delphi process with multidisciplinary, U.S.-based experts, using a consensus threshold of ≥
- Routine genital assessment is advised as part of comprehensive skin exams
- Verbal consent, stigma-reducing communication, and offering a chaperone to minors are emphasized as best practices
- Age-specific treatment considerations are detailed for pediatric, adult, and older populations
- Minimizing long-term topical corticosteroid use and considering non-steroidal options, when appropriate, are reinforced
“By raising awareness of genital psoriasis and providing guidance across different age groups, these recommendations can help support earlier diagnosis, improve engagement and adherence, and ultimately deliver more personalized and effective dermatologic care,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis. “When treatment plans are tailored to the individual and simplified wherever possible, patients are more likely to stay engaged in their care and achieve better outcomes. That belief is central to Arcutis’ ongoing commitment to advancing education and helping establish more thoughtful, personalized standards of care for high-impact dermatologic conditions across all ages.”
The Genital Psoriasis Wellness Consortium, supported by Arcutis, is a multidisciplinary group of clinicians who are experts in the diagnosis and management of genital psoriasis. The Consortium's work is designed to increase awareness of genital psoriasis as a common yet under-recognized manifestation with significant quality-of-life impact, advance clinician understanding of age-specific diagnostic and treatment considerations, and provide credible, clinician-focused educational content. The Consortium reflects Arcutis' broader commitment to leading education and elevating standards of care in sensitive, high-impact dermatologic conditions and to translating that scientific understanding into meaningful, real-world improvements in patient care.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise, allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/7e4b6752-0f96-4154-a127-d4bae05e4d3b
